{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:14:01Z","timestamp":1772003641521,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01648-z","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:05:22Z","timestamp":1769238322000},"page":"1411-1417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04006457","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rahmat","family":"Ishowo-Adejumo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Zareba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"1648_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14:81\u20139.","journal-title":"Autoimmun Rev"},{"key":"1648_CR2","doi-asserted-by":"crossref","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral JAK3\/TEC family kinase inhibitor ritlecitinib over 24\u00a0months: integrated analysis of the ALLEGRO phase\u00a02b\/3 and long-term phase\u00a03 clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327.","DOI":"10.1093\/bjd\/ljae365"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase\u00a02b\u20133 trial. Lancet. 2023;401:1518\u201329.","journal-title":"Lancet"},{"key":"1648_CR4","doi-asserted-by":"publisher","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","volume":"14","author":"T Passeron","year":"2023","unstructured":"Passeron T, King B, Seneschal J, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556.","journal-title":"Front Immunol"},{"key":"1648_CR5","unstructured":"Package Insert - Adacel. fda.gov: FDA, 2019."},{"key":"1648_CR6","unstructured":"Smith M. Package Insert - MENVEO. fda.gov: FDA, 2018."},{"key":"1648_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.15585\/mmwr.mm7301a3","volume":"73","author":"N Murthy","year":"2024","unstructured":"Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:11\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309\u201318.","journal-title":"Clin Infect Dis"},{"key":"1648_CR9","unstructured":"Altered Immunocompetence. cdc.gov: CDC; 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-best-practices\/altered-immunocompetence.html."},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham","year":"2010","unstructured":"Bingham CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64\u201374.","journal-title":"Arthritis Rheum"},{"key":"1648_CR11","first-page":"1122","volume":"12","author":"C Brodmerkel","year":"2013","unstructured":"Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013;12:1122\u20139.","journal-title":"J Drugs Dermatol"},{"key":"1648_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","volume":"80","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80:158-67.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1648_CR13","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1016\/j.vaccine.2023.04.056","volume":"41","author":"M Ohm","year":"2023","unstructured":"Ohm M, van Straalen JW, Zijlstra M, et al. Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: a prospective observational cohort study. Vaccine. 2023;41:3782\u20139.","journal-title":"Vaccine"},{"key":"1648_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jpids\/pix113","volume":"8","author":"SA Halperin","year":"2019","unstructured":"Halperin SA, Donovan C, Marshall GS, et al. Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10\u00a0years after a previous dose. J Pediatr Infect Dis Soc. 2019;8:105\u201314.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1648_CR15","unstructured":"EMA. Menveo Summary of Product Characteristics. https:\/\/www.ema.europa.eu."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01648-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:58Z","timestamp":1772001658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01648-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rahmat Ishowo-Adejumo, Agnieszka Zareba, Dalia Wajsbrot, and Robert Wolk are employees of and may hold stock or stock options in Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This sub-study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by each center\u2019s institutional review board or ethics committee. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}